Johnson & Johnson reports data from Phase 3 Iconic-Advance studies

Johnson & Johnson announced new data from the Phase 3 Iconic-Advance 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis. These data are being presented at the 2025 European Academy of Dermatology and Venereology, or EADV, Congress. Additionally, new long-term 52-week data from the Phase 3 ICONIC-LEAD study investigating icotrokinra in adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis will be presented as a late-breaking abstract at EADV. Icotrokinra met both co-primary endpoints compared to placebo at Week 16 with similar adverse event rates and showed superiority to deucravacitinib at multiple timepoints in adult patients in the ICONIC-ADVANCE 1 and 2 studies Icotrokinra showed superior skin clearance vs placebo and deucravacitinib. Icotrokinra demonstrated similar adverse event rates to placebo, with no new safety signals identified. Icotrokinra AE rates were numerically lower vs deucravacitinib through Week 24. Johnson & Johnson has also initiated the Phase 3 ICONIC-ASCEND study,c the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab, in psoriasis, representing an important step forward in psoriasis research.